SlideShare a Scribd company logo
All of Us Research Program—Protocol v1.12
IRB Approval Date: 23 October 2019
Protocol Title All of Us Research Program 1
Principal Investigator(s) Joshua Denny, M.D., M.S.
Vanderbilt University Medical Center
+1 615 936-5033
Sponsor National Institutes of Health (NIH)
Primary Contact John Wilbanks
Sage Bionetworks
+1 617 838-6333
Protocol Version Core Protocol v.1.12 pre02
Date 16 October 2019
IRB reference AoU IRB Protocol # 2017-05
IRB Approval date v1.5: May 20, 2017
v1.6: Feb 13, 2018
v1.7: Mar 28, 2018
v1.8: Jul 11, 2018
v1.9 Oct 19, 2018
v1.10 Mar 05, 2019
v1.11 Aug 12, 2019
v1.12 Oct 23, 2019
1 Precision Medicine Initiative, PMI, All of Us, the All of Us
logo, and “The Future of Health Begins
with You” are service marks of the U.S. Department of Health
and Human Services.
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
2
Program Leadership and Governance
Leadership
The All of Us Research Program (AoURP) is a large
collaborative initiative sponsored by the
National Institutes of Health (NIH). The research program
functions as a consortium of awardees
from multiple institutions. Its governance involves
representation from each awardee and
participant representatives. The consortium also includes the
program director and project
scientists/specialists from NIH. Each awardee has
responsibilities commensurate with expertise. See
Table 0–1: Program Unit Awardees for a list of NIH-funded
awardees and contact Principal
Investigators (PIs).
Dr. Joshua Denny of Vanderbilt University Medical Center
serves as the Principal Investigator on
behalf of the consortium.
Governance
The Steering Committee (SC) is the primary governing body of
AoURP. The SC recommends
strategic directions for the program and oversees planning,
coordination, and implementation of the
program’s overall operations. Its 50 voting members include PIs
from each awardee as designated
in the notice of award; representation from NIH, comprising of
the deputy director and chief
officers of AoURP; representation from community partners and
participants (see section 3.1); and
additional representation as needed to ensure balanced
representation of stakeholders. The
governance also includes an Executive Committee (EC) which is
a small governing body composed
of 17 members, that ensures the program is effectively meeting
its objectives and mission. The EC
proposes solutions to challenges and provides the Director with
strategies, options, and information
to aid in programmatic decisions. The Director has discretion to
delegate specific decisions to the
EC. Membership of the EC is determined by the Director and
reflects the awardees within the
consortium with balanced interests to ensure effective
deliberation.
The Steering Committee may approve the formation of
additional governance bodies– committees,
task forces, boards, etc. – as necessary to fulfill the mission of
AoURP. The purpose of these
additional governance bodies is to alleviate the bandwidth
constraints of the SC and EC by
gathering subject-matter experts from within the consortium to
oversee discussion and develop
policies, recommendations, or guidelines related to their
assigned topic.
Figure 0–1: Governance Structure
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
3
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
4
Table 0–1: Program Unit Awardees
Biobank
Stephen Thibodeau Mayo Clinic
Communications Awardees
Ronnie Tepp HCM
Patrick McGovern Wondros
DRC—Data and Research Center
Sekar Kathiresan Broad Institute
Joshua Denny Vanderbilt University Medical Center
David Glazer Verily
HPOs—Health Care Provider Organizations Primary Sites
RMCs—Regional Medical Centers (Contact PIs listed)
David Goldstein New York City Precision Medicine Consortium
Lucila Ohno-Machado California Precision Medicine
Consortium
Christine Johnson Henry Ford Health System
Jordan Smoller New England Precision Medicine Consortium
Philip Greenland Illinois Precision Medicine Consortium
Akinlolu Ojo University of Arizona
Steve Reis University of Pittsburgh
Bruce Korf University of Alabama at Birmingham
Murray Brilliant Marshfield Clinic Research Institute
Stephan Zuchner University of Miami Health System
FQHCs—Federally Qualified Health Centers
Parinda Khatri Cherokee Health Systems
Yashoda Sharma Community Health Center, Inc.
Eric Schlueter Eau Claire Cooperative Health Center
Carmen Chinea HRHCare
Donna Antoine-LaVigne Jackson-Hinds Comprehensive
Health Center
Fatima Muñoz San Ysidro Health Center
VAMCs—Veterans Affairs Medical Centers
Christopher J. O’Donnell United States Department of
Veterans Affairs
PTSC—Participant Technology Systems Center
Praduman Jain Vibrent Health
TPC—The Participant Center
Eric Topol Scripps Translational Science Institute
Community Partner Awards
Patricia Watkins Lattimore Delta Research and Educational
Foundation
Edgar Gil Rico National Alliance for Hispanic Health
Mitchell Lunn San Francisco General Hospital Foundation
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
5
Gretchen Funk Fifty Forward
Fornessa T. Randal The Asian Health Coalition
For more information, see
https://allofus.nih.gov/funding/awardees
https://allofus.nih.gov/funding/awardees
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
6
Table of Contents
PROGRAM LEADERSHIP AND GOVERNANCE
...............................................................................................
.. 2
1 BACKGROUND AND SCIENTIFIC RATIONALE
.................................................................................... 11
1.1 PILOT ACTIVITIES
...............................................................................................
.............................................................. 11
2 OBJECTIVES
...............................................................................................
................................................. 14
2.1 WHAT IS THE ALL OF US RESEARCH
PROGRAM?............................................................................
.......................... 14
3 STUDY OVERVIEW
...............................................................................................
..................................... 15
3.1 PARTICIPANTS REPRESENTATIVES
...............................................................................................
............................... 16
3.2 CREATING A RESOURCE FOR RESEARCH
...............................................................................................
...................... 17
3.3 MAKING THE RESOURCE ACCESSIBLE FOR
RESEARCH
............................................................................................
19
3.4 STUDY TIMELINE/STUDY DURATION
...............................................................................................
........................... 20
4 SELECTION OF PARTICIPANTS
...............................................................................................
............... 20
4.1
ELIGIBILITY..........................................................................
...............................................................................................
20
4.2 INCLUSION AND EXCLUSION CRITERIA
...............................................................................................
......................... 21
4.3 VULNERABLE POPULATIONS
...............................................................................................
........................................... 21
5 RECRUITMENT OUTREACH
...............................................................................................
..................... 22
5.1 OUTREACH TO HPO MEMBERS
...............................................................................................
...................................... 23
5.2 OUTREACH TO DIRECT VOLUNTEERS
...............................................................................................
........................... 24
5.3 THE SUPPORT CENTER
...............................................................................................
..................................................... 24
5.4 OUTREACH TO COMMUNITIES
............................................................................... ................
........................................ 25
5.5 MOBILE ENGAGEMENT ASSET
...............................................................................................
........................................ 27
5.6 SUMMARY OF OUTREACH AND ENGAGEMENT
APPROACHES
................................................................................ 27
5.7 READABILITY OF OUTREACH AND ENROLLMENT
MATERIALS
............................................................................. 28
6 ENROLLMENT
...............................................................................................
............................................. 29
6.1 ENROLLMENT STRATEGIES
.................................................................................... ...........
.............................................. 29
6.2 LEVELS OF
ENROLLMENT.......................................................................
......................................................................... 29
6.3 ACCOUNT CREATION
...............................................................................................
......................................................... 31
6.4 INFORMATION COLLECTED PRIOR TO INFORMED
CONSENT
................................................................................. 31
6.5 INFORMED CONSENT OVERVIEW
...............................................................................................
................................... 31
6.6 ELECTRONIC CONSENT
...............................................................................................
..................................................... 33
6.7 DATA OVERSIGHT AND CHOICE OF LAW
...............................................................................................
...................... 37
6.8 MONITORING ENROLLMENT
...............................................................................................
........................................... 38
7 WHAT IS INVOLVED? PROGRAM
PROCEDURES........................................................................
........ 41
7.1 PARTICIPANT-PROVIDED INFORMATION (PPI)
...............................................................................................
........ 42
7.2 USE OF PERSONAL HEALTH TECHNOLOGIES
...............................................................................................
.............. 43
7.3 PHYSICAL MEASUREMENTS
...............................................................................................
............................................. 45
7.4 BIOSPECIMEN COLLECTION
...............................................................................................
............................................. 46
7.5 BIOSPECIMEN PROCESSING AND STORAGE
...............................................................................................
................. 48
7.6 ELECTRONIC HEALTH RECORDS (EHRS)
...............................................................................................
.................... 51
7.7 DATA LINKAGE
...............................................................................................
................................................................... 51
7.8 EARLY AND LONG-TERM PARTICIPANT
INVOLVEMENT
......................................................................................... 53
8 RISKS/BENEFITS ASSESSMENT
...............................................................................................
.............. 56
8.1 RISKS
...............................................................................................
..................................................................................... 56
8.2 BENEFITS
.......................................................................................... .....
............................................................................. 58
8.3 RISK/BENEFIT ANALYSIS
...............................................................................................
................................................ 60
9 ISSUES TO CONSIDER
...............................................................................................
................................ 60
9.1 PAYMENT FOR PARTICIPANTS
...............................................................................................
........................................ 60
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
7
9.2 HANDLING ON-SITE REPORTABLE EVENTS
...............................................................................................
................ 61
9.3 PARTICIPATION OPTIONS: DEACTIVATE AND
WITHDRAWAL PROCEDURES
..................................................... 62
9.4 DESTRUCTION OF
SPECIMENS...........................................................................
............................................................. 64
10 ACCESS TO INDIVIDUAL-LEVEL INFORMATION FOR
PARTICIPANTS ......................................... 65
10.1 PRINCIPLES OF INDIVIDUAL-LEVEL INFORMATION
AVAILABILITY .....................................................................
65
10.2 INDIVIDUAL-LEVEL PROGRAM INFORMATION
...............................................................................................
........... 65
10.3 INFORMATION ACCESS TECHNOLOGIES
...............................................................................................
....................... 67
10.4 INDIVIDUAL-LEVEL INFORMATION ACCESS
PROCESSES...........................................................................
.............. 68
10.5 PHYSICAL MEASUREMENTS—RETURN OF
MEDICALLY ACTIONABLE
RESULTS.............................................. 70
10.6 PARTICIPANT-PROVIDED INFORMATION AND EHR
...............................................................................................
. 74
10.7 ACCESS TO BIOSPECIMEN-DERIVED INFORMATION
(NON-GENETIC) ................................................................
74
10.8 ACCESS TO GENOMIC RESULTS
...............................................................................................
....................................... 74
11 CREATION OF THE ALL OF US RESEARCH PROGRAM
RESOURCE................................................. 75
11.1 THE RAW DATA REPOSITORY
...............................................................................................
........................................ 75
11.2 THE CURATED DATA REPOSITORY
...............................................................................................
................................ 75
11.3 THE PTSC DATA REPOSITORY
...............................................................................................
....................................... 76
12 ACCESS TO THE RESOURCE FOR RESEARCH
...................................................................................... 77
12.1 ALL OF US DATA ACCESS GOVERNANCE
...............................................................................................
....................... 78
12.2 ACCESS AND USE OF DATA
...............................................................................................
.............................................. 79
12.3 ACCESS AND USE OF BIOSPECIMENS
...............................................................................................
............................. 82
12.4 CONTACTING PARTICIPANTS
...............................................................................................
.......................................... 82
13 CONFIDENTIALITY, PRIVACY, AND SECURITY
.................................................................................. 83
13.1 SECURITY POSTURE
...............................................................................................
........................................................... 84
13.2 FISMA AND ITS SIGNIFICANCE TO THE ALL OF US
RESEARCH PROGRAM .........................................................
84
13.1 OVERVIEW OF PRIVACY AND DATA
CONFIDENTIALITY PROTECTIONS
.............................................................. 87
14 POST-ENROLLMENT ENGAGEMENT STRATEGY
............................................................................... 91
14.1 CONCEPTUAL FRAMEWORK
...............................................................................................
............................................ 92
14.2 APPROACH TO ENGAGEMENT
...............................................................................................
......................................... 93
14.3 RETENTION
...............................................................................................
.......................................................................... 95
15 SITE MONITORING, RECORD KEEPING, AND QUALITY
ASSURANCE ........................................... 98
15.1 HPO AND DV ENROLLMENT SITE MONITORING
...............................................................................................
...... 98
15.2 TRAINING EXPECTATIONS
........................................................................................... ....
................................................ 99
16 REFERENCES
...............................................................................................
............................................. 101
17 LIST OF TERMS AND ACRONYMS
...............................................................................................
......... 103
18 LIST OF APPENDICES
...............................................................................................
.............................. 107
19 PROTOCOL VERSIONS
...............................................................................................
............................. 108
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
8
Table of Tables
TABLE 0–1: PROGRAM UNIT AWARDEES
...............................................................................................
........................................... 4
TABLE 0–2: PROTOCOL SYNOPSIS
...............................................................................................
......................................................... 9
TABLE 4–1: VULNERABLE POPULATIONS EXCLUDED AT
LAUNCH................................................................................
....... 22
TABLE 7–1: ESTIMATED DURATION OF PARTICIPANT
JOURNEY
.......................................................................................... 41
TABLE 7–2: SURVEY COMPLETION TIMES
...................................................................................... .........
....................................... 43
TABLE 7–3: QUESTIONS TO PARTICIPANTS PRIOR TO
SCHEDULING THE BLOOD SAMPLE COLLECTION ............
47
TABLE 9–1: PARTICIPATION OPTIONS
...............................................................................................
.............................................. 62
TABLE 10–1: MEDICALLY ACTIONABLE FINDINGS AT
THE TIME OF BASELINE PHYSICAL MEASUREMENTS ....
70
TABLE 12–1: DATA ACCESS BY TYPE
...............................................................................................
................................................. 81
TABLE 13–1: THREAT ASSESSMENT
...............................................................................................
.................................................. 88
Table of Figures
FIGURE 0–1: GOVERNANCE STRUCTURE
...............................................................................................
............................................ 2
FIGURE 1–1: PPI DEVELOPMENT PROCEDURE
...............................................................................................
.............................. 12
FIGURE 3–1: PARTICIPANT INTERACTION FLOW
............................................................................... ................
......................... 19
FIGURE 6–1: PARTICIPANT JOURNEY
...............................................................................................
................................................ 30
FIGURE 7–1: BIOSPECIMEN FLOWCHART
...............................................................................................
........................................ 49
FIGURE 7–2: DATA WORKFLOW SAMPLE FOR
PARTICIPANTS......................................................................
......................... 54
FIGURE 10–1: ALL OF US RESEARCH PROGRAM
INDIVIDUAL-LEVEL INFORMATION: DATA AND
RESULTS......... 66
FIGURE 10–2: DATA FLOW FOR PARTICIPANTS AND HPO
STAFF
......................................................................................... 68
FIGURE 10–3 EXAMPLE OF PHYSICAL MEASUREMENT
CARD—CO-BRANDED
................................................................ 72
FIGURE 10–4 EXAMPLE OF PHYSICAL MEASUREMENT
CARD—5 X7 FORMAT
................................................................ 73
FIGURE 11–1: CURATED DATASET
...............................................................................................
..................................................... 77
FIGURE 13–1: ALL OF US RESEARCH PROGRAM
CONNECTIONS AND DATA FLOW
........................................................ 84
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
9
Protocol Synopsis
Table 0–2: Protocol Synopsis
TITLE All of Us Research Program (All of Us)
SPONSOR National Institutes of Health (NIH)
FUNDING
ORGANIZATION
National Institutes of Health (NIH)
NUMBER OF SITES Multiple sites through selected Health
Care Provider organizations
(HPOs) and Direct Volunteer (DV) partners, and sites
representing
core functions, such as the Biobank, Data and Research Center
(DRC), Participant Technology Systems Center (PTSC), other
technology partners , and Community Partners.
RATIONALE Precision medicine is an approach to disease
treatment and prevention
that seeks to maximize effectiveness by considering individual
variability in genes, environment, and lifestyle. Precision
medicine
seeks to redefine our understanding of disease onset and
progression,
treatment response, and health outcomes through the more
precise
measurement of molecular, environmental, physiologic, and
behavioral factors that contribute to health and disease. This
understanding will lead to more accurate diagnoses, more
rational
disease prevention strategies, better treatment selection, and the
development of novel therapies.
By enrolling a diverse group of one million or more participants
who
provide questionnaire responses—participant-provided
information
(PPI), electronic health record (EHR) data, biospecimens,
physical
measurements, and permission for re-contact—for many years,
the All
of Us Research Program will have the scale and scope to enable
research for a wide range of diseases, both common and rare, as
well
as increasing our understanding of healthy states.
STUDY DESIGN At its core, this is a large longitudinal cohort
program with repeated
engagement of participants to create a research resource that
enables a
variety of future observational and interventional studies, some
of
which will require subsequent IRB approvals.
PRIMARY OBJECTIVE To build a robust research resource
composed of PPI, environmental,
physiologic, genetic, and health data plus biospecimens from
one
million or more research participants reflecting the diversity of
the
United States.
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
10
This resource will facilitate the exploration of biological,
social, and
environmental determinants of health and disease.
NUMBER OF
PARTICIPANTS AND
ENROLLMENT
MODES
One million or more individuals willing and able to answer
questionnaires (PPI), provide biospecimens and physical
measurements, share their EHR data, and authorize re-contact
will be
enrolled via two modes, whichever is most convenient for the
participant: through HPOs or DV sites, using digital interfaces.
We
expect that many more than one million individuals may enroll
into
the cohort and complete some of these components (see Section
4,
Selection of Participants).
PARTICIPANT
SELECTION
CRITERIA
Inclusion Criteria:
• Adults 18 and older with decisional capacity to consent
• Currently reside in the United States or a territory of the
United States
Exclusion Criteria:
• Prisoners at the time of enrollment
DURATION OF
PARTICIPATION AND
DURATION OF STUDY
Duration of Study: The All of Us Research Program is expected
to
last at least 10 years, with active enrollment occurring in the
first five
years.
Duration of Participation: Participation is expected to last for
the
entire duration of the research program, with regular data
contribution
and follow-up.
PRIMARY ENDPOINT Collection and curation of rich
participant health and biospecimen
data accessible to the research community, to enable a broad
spectrum
of research studies.
SECONDARY
ENDPOINTS
Build the infrastructure to enroll participants, collect
biospecimens,
and securely share health-related data for ongoing research.
SAFETY
EVALUATIONS
Safeguards are in place to maintain the privacy of the
participants, the
confidentiality of the biospecimens, and the security of the data
collected through the research program (see Section 13,
Confidentiality, Privacy, and Security).
All of Us Research Program—Protocol v1.11 pre02
IRB Approval Date
11
1 Background and Scientific Rationale
Our current approach to health care is informed by clinical
trials that have sample sizes in the
thousands, or tens of thousands, meaning that we typically lack
the statistical power to make fine-
grained predictions about how a given treatment will affect a
given individual. As a result, therapies
often fail in practice and most interventions fail to integrate
with most patients’ own knowledge and
lifestyles. Historically, this approach is characterized by a lack
of inclusion and diversity in clinical
study; that is, the benefits of precise and personalized
interventions may not be accruing equitably
across society.
Precision medicine is an approach to disease prevention,
diagnosis, and treatment that seeks to
maximize effectiveness by considering individual variability in
genes, environment, and lifestyle.
Precision medicine seeks to redefine our understanding of
disease onset and progression, treatment
response, and health outcomes through the combined analysis of
biological, environmental, and
behavioral factors that contribute to health and disease. This
understanding may lead to more
rational disease prevention strategies, more accurate diagnoses,
better treatment selection, and the
development of novel therapies. The promise of precision
medicine can only be achieved with input
from a broad population that reflects the true diversity and life
experiences of those in the United
States.
By combining health-related information from one million or
more diverse participants, the All of
Us Research Program will have the right scale and inclusive
scope to enable research for a wide
range of diseases, both common and rare. A cohort of this size
will have the statistical power to
detect associations between genetic and environmental
exposures and a wide variety of health
outcomes. A deliberately inclusive strategy that prioritizes
groups historically underrepresented in
biomedical research (UBR) should provide enough power for
meaningful subgroup analyses and
lead to the most precise medicine for these groups. Outcomes of
this research could include novel
prevention and screening strategies, earlier and more precise
diagnoses, new and more rational use
of therapies, and improved understanding of why some people
remain healthy despite exposures
and risk factors for disease.
Coincident with advancing the science of medicine is a
changing culture of health care practice and
biomedical research that engages individuals as active partners.
The All of Us Research Program
aims to actively engage participants and their advocates in all
aspects of the research program,
including governance, oversight, design, conduct,
dissemination, and evaluation. Participants will
not only provide their biological, health, behavioral, and
environmental data, they will also be able
to access their information, learn about the research being
conducted, and be partners in the
discovery process. This ongoing partnership between the
research program and participants is
described in Section 14, …
All of Us Research Program—Protocol v1.12 IRB Approval Dat.docx

More Related Content

Similar to All of Us Research Program—Protocol v1.12 IRB Approval Dat.docx

PCPCC Medical Home update, April 2010
PCPCC Medical Home update, April 2010PCPCC Medical Home update, April 2010
PCPCC Medical Home update, April 2010
e-Patient Dave deBronkart
 
Public reports pack 17032016 1915 Healthier Communities and Older People Over...
Public reports pack 17032016 1915 Healthier Communities and Older People Over...Public reports pack 17032016 1915 Healthier Communities and Older People Over...
Public reports pack 17032016 1915 Healthier Communities and Older People Over...Nicola Nadanakumaran
 
Public Financial Management, Health Governance, and Health Systems
Public Financial Management, Health Governance, and Health SystemsPublic Financial Management, Health Governance, and Health Systems
Public Financial Management, Health Governance, and Health Systems
HFG Project
 
Better Health? Composite Evidence from Four Literature Reviews
Better Health? Composite Evidence from Four Literature ReviewsBetter Health? Composite Evidence from Four Literature Reviews
Better Health? Composite Evidence from Four Literature Reviews
HFG Project
 
Final eHO EMR Benefits Report Jan2013
Final eHO EMR Benefits Report Jan2013Final eHO EMR Benefits Report Jan2013
Final eHO EMR Benefits Report Jan2013Emmanuel Casalino
 
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssembly
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssemblyHealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssembly
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssemblyKim Paull
 
Indian Council of Medical Research (ICMR).pptx
Indian Council of Medical Research (ICMR).pptxIndian Council of Medical Research (ICMR).pptx
Indian Council of Medical Research (ICMR).pptx
SamikshaHamane
 
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
Chuchai Sornchumni
 
Meaningful Use When 5 19 10
Meaningful Use When 5 19 10Meaningful Use When 5 19 10
Meaningful Use When 5 19 10
Paula Zalucki, FACHE
 
HIT Policy Committee Information Exchange Workgroup 9-13-10
HIT Policy Committee Information Exchange Workgroup 9-13-10HIT Policy Committee Information Exchange Workgroup 9-13-10
HIT Policy Committee Information Exchange Workgroup 9-13-10Brian Ahier
 
An Emergent Research And Policy Framework For Telehealth
An Emergent Research And Policy Framework For TelehealthAn Emergent Research And Policy Framework For Telehealth
An Emergent Research And Policy Framework For Telehealth
Yasmine Anino
 
Eysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
Eysenbach AMIA Keynote: From Patient Needs to Personal Health ApplicationsEysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
Eysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
Gunther Eysenbach
 
Eysenbach: Personal Health Applications and Personal Health Records
Eysenbach: Personal Health Applications and Personal Health RecordsEysenbach: Personal Health Applications and Personal Health Records
Eysenbach: Personal Health Applications and Personal Health Records
Gunther Eysenbach
 
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
Mondher Daghfous
 
Health Impact Assessment - INPES Journées de la prévention 2015
Health Impact Assessment - INPES Journées de la prévention 2015Health Impact Assessment - INPES Journées de la prévention 2015
Health Impact Assessment - INPES Journées de la prévention 2015
Ben Harris-Roxas
 

Similar to All of Us Research Program—Protocol v1.12 IRB Approval Dat.docx (20)

The Power of Partnership in Research: Improving Healthcare Outcomes in Unders...
The Power of Partnership in Research: Improving Healthcare Outcomes in Unders...The Power of Partnership in Research: Improving Healthcare Outcomes in Unders...
The Power of Partnership in Research: Improving Healthcare Outcomes in Unders...
 
PCPCC Medical Home update, April 2010
PCPCC Medical Home update, April 2010PCPCC Medical Home update, April 2010
PCPCC Medical Home update, April 2010
 
Public reports pack 17032016 1915 Healthier Communities and Older People Over...
Public reports pack 17032016 1915 Healthier Communities and Older People Over...Public reports pack 17032016 1915 Healthier Communities and Older People Over...
Public reports pack 17032016 1915 Healthier Communities and Older People Over...
 
HIE Pilot Project
HIE Pilot ProjectHIE Pilot Project
HIE Pilot Project
 
Public Financial Management, Health Governance, and Health Systems
Public Financial Management, Health Governance, and Health SystemsPublic Financial Management, Health Governance, and Health Systems
Public Financial Management, Health Governance, and Health Systems
 
Better Health? Composite Evidence from Four Literature Reviews
Better Health? Composite Evidence from Four Literature ReviewsBetter Health? Composite Evidence from Four Literature Reviews
Better Health? Composite Evidence from Four Literature Reviews
 
Final eHO EMR Benefits Report Jan2013
Final eHO EMR Benefits Report Jan2013Final eHO EMR Benefits Report Jan2013
Final eHO EMR Benefits Report Jan2013
 
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssembly
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssemblyHealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssembly
HealthCarePlanningAccountabilityAdvisoryCouncillReportToGeneralAssembly
 
National Aboriginal Health Forum
National Aboriginal Health ForumNational Aboriginal Health Forum
National Aboriginal Health Forum
 
Indian Council of Medical Research (ICMR).pptx
Indian Council of Medical Research (ICMR).pptxIndian Council of Medical Research (ICMR).pptx
Indian Council of Medical Research (ICMR).pptx
 
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
ทบทวนประสบการณ์ Universal Health Coverage 11 ประเทศ
 
Hmn Arusha Symposium Jan09
Hmn Arusha Symposium Jan09Hmn Arusha Symposium Jan09
Hmn Arusha Symposium Jan09
 
Meaningful Use When 5 19 10
Meaningful Use When 5 19 10Meaningful Use When 5 19 10
Meaningful Use When 5 19 10
 
HIT Policy Committee Information Exchange Workgroup 9-13-10
HIT Policy Committee Information Exchange Workgroup 9-13-10HIT Policy Committee Information Exchange Workgroup 9-13-10
HIT Policy Committee Information Exchange Workgroup 9-13-10
 
An Emergent Research And Policy Framework For Telehealth
An Emergent Research And Policy Framework For TelehealthAn Emergent Research And Policy Framework For Telehealth
An Emergent Research And Policy Framework For Telehealth
 
What is a health system?
What is a health system?What is a health system?
What is a health system?
 
Eysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
Eysenbach AMIA Keynote: From Patient Needs to Personal Health ApplicationsEysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
Eysenbach AMIA Keynote: From Patient Needs to Personal Health Applications
 
Eysenbach: Personal Health Applications and Personal Health Records
Eysenbach: Personal Health Applications and Personal Health RecordsEysenbach: Personal Health Applications and Personal Health Records
Eysenbach: Personal Health Applications and Personal Health Records
 
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
Healthimpactassessment benharris-roxas-150610073811-lva1-app6892-1
 
Health Impact Assessment - INPES Journées de la prévention 2015
Health Impact Assessment - INPES Journées de la prévention 2015Health Impact Assessment - INPES Journées de la prévention 2015
Health Impact Assessment - INPES Journées de la prévention 2015
 

More from simonlbentley59018

Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docxAllison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
simonlbentley59018
 
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docxAllen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
simonlbentley59018
 
All workings, when appropriate, must be shown to substantiate your.docx
All workings, when appropriate, must be shown to substantiate your.docxAll workings, when appropriate, must be shown to substantiate your.docx
All workings, when appropriate, must be shown to substantiate your.docx
simonlbentley59018
 
All yellow highlight is missing answer, please answer all of t.docx
All yellow highlight is missing answer, please answer all of t.docxAll yellow highlight is missing answer, please answer all of t.docx
All yellow highlight is missing answer, please answer all of t.docx
simonlbentley59018
 
All models are wrong. Some models are useful.—George E. P. B.docx
All models are wrong. Some models are useful.—George E. P. B.docxAll models are wrong. Some models are useful.—George E. P. B.docx
All models are wrong. Some models are useful.—George E. P. B.docx
simonlbentley59018
 
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docxallclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
simonlbentley59018
 
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docxALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
simonlbentley59018
 
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docxALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
simonlbentley59018
 
All views expressed in this paper are those of the authors a.docx
All views expressed in this paper are those of the authors a.docxAll views expressed in this paper are those of the authors a.docx
All views expressed in this paper are those of the authors a.docx
simonlbentley59018
 
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docxAll Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
simonlbentley59018
 
All three of the Aristotle, Hobbes, and Douglass readings discussed .docx
All three of the Aristotle, Hobbes, and Douglass readings discussed .docxAll three of the Aristotle, Hobbes, and Douglass readings discussed .docx
All three of the Aristotle, Hobbes, and Douglass readings discussed .docx
simonlbentley59018
 
All rights reserved. No part of this report, including t.docx
All rights reserved. No part of this report, including t.docxAll rights reserved. No part of this report, including t.docx
All rights reserved. No part of this report, including t.docx
simonlbentley59018
 
All PrinciplesEvidence on Persuasion Principles This provides som.docx
All PrinciplesEvidence on Persuasion Principles This provides som.docxAll PrinciplesEvidence on Persuasion Principles This provides som.docx
All PrinciplesEvidence on Persuasion Principles This provides som.docx
simonlbentley59018
 
All papers may be subject to submission for textual similarity revie.docx
All papers may be subject to submission for textual similarity revie.docxAll papers may be subject to submission for textual similarity revie.docx
All papers may be subject to submission for textual similarity revie.docx
simonlbentley59018
 
All of us live near some major industry. Describe the history of an .docx
All of us live near some major industry. Describe the history of an .docxAll of us live near some major industry. Describe the history of an .docx
All of us live near some major industry. Describe the history of an .docx
simonlbentley59018
 
All participants must read the following article ATTACHED Agwu.docx
All participants must read the following article ATTACHED Agwu.docxAll participants must read the following article ATTACHED Agwu.docx
All participants must read the following article ATTACHED Agwu.docx
simonlbentley59018
 
ALL of the requirements are contained in the attached document.  T.docx
ALL of the requirements are contained in the attached document.  T.docxALL of the requirements are contained in the attached document.  T.docx
ALL of the requirements are contained in the attached document.  T.docx
simonlbentley59018
 
All five honorees cared greatly about the success of Capella lea.docx
All five honorees cared greatly about the success of Capella lea.docxAll five honorees cared greatly about the success of Capella lea.docx
All five honorees cared greatly about the success of Capella lea.docx
simonlbentley59018
 
All of the instructions will be given to you in a document. One docu.docx
All of the instructions will be given to you in a document. One docu.docxAll of the instructions will be given to you in a document. One docu.docx
All of the instructions will be given to you in a document. One docu.docx
simonlbentley59018
 
All financial statement audits will include an audit of the inve.docx
All financial statement audits will include an audit of the inve.docxAll financial statement audits will include an audit of the inve.docx
All financial statement audits will include an audit of the inve.docx
simonlbentley59018
 

More from simonlbentley59018 (20)

Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docxAllison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
Allison RogersProfessor KoenigCOMM 3313October 12th, 2018H.docx
 
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docxAllen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
Allen 1Kiah AllenProfessor HirschENG1018 Feb. 2018Defo.docx
 
All workings, when appropriate, must be shown to substantiate your.docx
All workings, when appropriate, must be shown to substantiate your.docxAll workings, when appropriate, must be shown to substantiate your.docx
All workings, when appropriate, must be shown to substantiate your.docx
 
All yellow highlight is missing answer, please answer all of t.docx
All yellow highlight is missing answer, please answer all of t.docxAll yellow highlight is missing answer, please answer all of t.docx
All yellow highlight is missing answer, please answer all of t.docx
 
All models are wrong. Some models are useful.—George E. P. B.docx
All models are wrong. Some models are useful.—George E. P. B.docxAll models are wrong. Some models are useful.—George E. P. B.docx
All models are wrong. Some models are useful.—George E. P. B.docx
 
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docxallclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
allclasses-frame.htmlAll ClassesAIBoardPlacementRandomModeRotati.docx
 
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docxALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
ALL WORK MUST BE ORIGINAL, CITED, IN APA FORMAT & WILL BE SUBMITTED .docx
 
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docxALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
ALL WORK MUST BE ORIGINAL, CITED IN APA FORMAT AND WILL BE SUBMITTED.docx
 
All views expressed in this paper are those of the authors a.docx
All views expressed in this paper are those of the authors a.docxAll views expressed in this paper are those of the authors a.docx
All views expressed in this paper are those of the authors a.docx
 
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docxAll Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
All Wet! Legacy of Juniper Utility has residents stewingBy Eri.docx
 
All three of the Aristotle, Hobbes, and Douglass readings discussed .docx
All three of the Aristotle, Hobbes, and Douglass readings discussed .docxAll three of the Aristotle, Hobbes, and Douglass readings discussed .docx
All three of the Aristotle, Hobbes, and Douglass readings discussed .docx
 
All rights reserved. No part of this report, including t.docx
All rights reserved. No part of this report, including t.docxAll rights reserved. No part of this report, including t.docx
All rights reserved. No part of this report, including t.docx
 
All PrinciplesEvidence on Persuasion Principles This provides som.docx
All PrinciplesEvidence on Persuasion Principles This provides som.docxAll PrinciplesEvidence on Persuasion Principles This provides som.docx
All PrinciplesEvidence on Persuasion Principles This provides som.docx
 
All papers may be subject to submission for textual similarity revie.docx
All papers may be subject to submission for textual similarity revie.docxAll papers may be subject to submission for textual similarity revie.docx
All papers may be subject to submission for textual similarity revie.docx
 
All of us live near some major industry. Describe the history of an .docx
All of us live near some major industry. Describe the history of an .docxAll of us live near some major industry. Describe the history of an .docx
All of us live near some major industry. Describe the history of an .docx
 
All participants must read the following article ATTACHED Agwu.docx
All participants must read the following article ATTACHED Agwu.docxAll participants must read the following article ATTACHED Agwu.docx
All participants must read the following article ATTACHED Agwu.docx
 
ALL of the requirements are contained in the attached document.  T.docx
ALL of the requirements are contained in the attached document.  T.docxALL of the requirements are contained in the attached document.  T.docx
ALL of the requirements are contained in the attached document.  T.docx
 
All five honorees cared greatly about the success of Capella lea.docx
All five honorees cared greatly about the success of Capella lea.docxAll five honorees cared greatly about the success of Capella lea.docx
All five honorees cared greatly about the success of Capella lea.docx
 
All of the instructions will be given to you in a document. One docu.docx
All of the instructions will be given to you in a document. One docu.docxAll of the instructions will be given to you in a document. One docu.docx
All of the instructions will be given to you in a document. One docu.docx
 
All financial statement audits will include an audit of the inve.docx
All financial statement audits will include an audit of the inve.docxAll financial statement audits will include an audit of the inve.docx
All financial statement audits will include an audit of the inve.docx
 

Recently uploaded

The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
Nguyen Thanh Tu Collection
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
Vivekanand Anglo Vedic Academy
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
Steve Thomason
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
AzmatAli747758
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
Col Mukteshwar Prasad
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
rosedainty
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 

Recently uploaded (20)

The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
 

All of Us Research Program—Protocol v1.12 IRB Approval Dat.docx

  • 1. All of Us Research Program—Protocol v1.12 IRB Approval Date: 23 October 2019 Protocol Title All of Us Research Program 1 Principal Investigator(s) Joshua Denny, M.D., M.S. Vanderbilt University Medical Center +1 615 936-5033 Sponsor National Institutes of Health (NIH) Primary Contact John Wilbanks Sage Bionetworks +1 617 838-6333 Protocol Version Core Protocol v.1.12 pre02 Date 16 October 2019 IRB reference AoU IRB Protocol # 2017-05 IRB Approval date v1.5: May 20, 2017 v1.6: Feb 13, 2018 v1.7: Mar 28, 2018 v1.8: Jul 11, 2018 v1.9 Oct 19, 2018 v1.10 Mar 05, 2019
  • 2. v1.11 Aug 12, 2019 v1.12 Oct 23, 2019 1 Precision Medicine Initiative, PMI, All of Us, the All of Us logo, and “The Future of Health Begins with You” are service marks of the U.S. Department of Health and Human Services. All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 2 Program Leadership and Governance Leadership The All of Us Research Program (AoURP) is a large collaborative initiative sponsored by the National Institutes of Health (NIH). The research program functions as a consortium of awardees from multiple institutions. Its governance involves representation from each awardee and participant representatives. The consortium also includes the program director and project scientists/specialists from NIH. Each awardee has responsibilities commensurate with expertise. See Table 0–1: Program Unit Awardees for a list of NIH-funded
  • 3. awardees and contact Principal Investigators (PIs). Dr. Joshua Denny of Vanderbilt University Medical Center serves as the Principal Investigator on behalf of the consortium. Governance The Steering Committee (SC) is the primary governing body of AoURP. The SC recommends strategic directions for the program and oversees planning, coordination, and implementation of the program’s overall operations. Its 50 voting members include PIs from each awardee as designated in the notice of award; representation from NIH, comprising of the deputy director and chief officers of AoURP; representation from community partners and participants (see section 3.1); and additional representation as needed to ensure balanced representation of stakeholders. The governance also includes an Executive Committee (EC) which is a small governing body composed of 17 members, that ensures the program is effectively meeting its objectives and mission. The EC proposes solutions to challenges and provides the Director with strategies, options, and information to aid in programmatic decisions. The Director has discretion to delegate specific decisions to the EC. Membership of the EC is determined by the Director and reflects the awardees within the consortium with balanced interests to ensure effective deliberation. The Steering Committee may approve the formation of additional governance bodies– committees,
  • 4. task forces, boards, etc. – as necessary to fulfill the mission of AoURP. The purpose of these additional governance bodies is to alleviate the bandwidth constraints of the SC and EC by gathering subject-matter experts from within the consortium to oversee discussion and develop policies, recommendations, or guidelines related to their assigned topic. Figure 0–1: Governance Structure All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 3 All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 4 Table 0–1: Program Unit Awardees Biobank Stephen Thibodeau Mayo Clinic
  • 5. Communications Awardees Ronnie Tepp HCM Patrick McGovern Wondros DRC—Data and Research Center Sekar Kathiresan Broad Institute Joshua Denny Vanderbilt University Medical Center David Glazer Verily HPOs—Health Care Provider Organizations Primary Sites RMCs—Regional Medical Centers (Contact PIs listed) David Goldstein New York City Precision Medicine Consortium Lucila Ohno-Machado California Precision Medicine Consortium Christine Johnson Henry Ford Health System Jordan Smoller New England Precision Medicine Consortium Philip Greenland Illinois Precision Medicine Consortium Akinlolu Ojo University of Arizona Steve Reis University of Pittsburgh Bruce Korf University of Alabama at Birmingham Murray Brilliant Marshfield Clinic Research Institute Stephan Zuchner University of Miami Health System FQHCs—Federally Qualified Health Centers Parinda Khatri Cherokee Health Systems Yashoda Sharma Community Health Center, Inc. Eric Schlueter Eau Claire Cooperative Health Center Carmen Chinea HRHCare Donna Antoine-LaVigne Jackson-Hinds Comprehensive Health Center
  • 6. Fatima Muñoz San Ysidro Health Center VAMCs—Veterans Affairs Medical Centers Christopher J. O’Donnell United States Department of Veterans Affairs PTSC—Participant Technology Systems Center Praduman Jain Vibrent Health TPC—The Participant Center Eric Topol Scripps Translational Science Institute Community Partner Awards Patricia Watkins Lattimore Delta Research and Educational Foundation Edgar Gil Rico National Alliance for Hispanic Health Mitchell Lunn San Francisco General Hospital Foundation All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 5 Gretchen Funk Fifty Forward Fornessa T. Randal The Asian Health Coalition For more information, see https://allofus.nih.gov/funding/awardees https://allofus.nih.gov/funding/awardees All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date
  • 7. 6 Table of Contents PROGRAM LEADERSHIP AND GOVERNANCE ............................................................................................... .. 2 1 BACKGROUND AND SCIENTIFIC RATIONALE .................................................................................... 11 1.1 PILOT ACTIVITIES ............................................................................................... .............................................................. 11 2 OBJECTIVES ............................................................................................... ................................................. 14 2.1 WHAT IS THE ALL OF US RESEARCH PROGRAM?............................................................................ .......................... 14 3 STUDY OVERVIEW ............................................................................................... ..................................... 15 3.1 PARTICIPANTS REPRESENTATIVES ............................................................................................... ............................... 16 3.2 CREATING A RESOURCE FOR RESEARCH ............................................................................................... ...................... 17 3.3 MAKING THE RESOURCE ACCESSIBLE FOR RESEARCH ............................................................................................ 19 3.4 STUDY TIMELINE/STUDY DURATION
  • 8. ............................................................................................... ........................... 20 4 SELECTION OF PARTICIPANTS ............................................................................................... ............... 20 4.1 ELIGIBILITY.......................................................................... ............................................................................................... 20 4.2 INCLUSION AND EXCLUSION CRITERIA ............................................................................................... ......................... 21 4.3 VULNERABLE POPULATIONS ............................................................................................... ........................................... 21 5 RECRUITMENT OUTREACH ............................................................................................... ..................... 22 5.1 OUTREACH TO HPO MEMBERS ............................................................................................... ...................................... 23 5.2 OUTREACH TO DIRECT VOLUNTEERS ............................................................................................... ........................... 24 5.3 THE SUPPORT CENTER ............................................................................................... ..................................................... 24 5.4 OUTREACH TO COMMUNITIES ............................................................................... ................ ........................................ 25 5.5 MOBILE ENGAGEMENT ASSET ............................................................................................... ........................................ 27 5.6 SUMMARY OF OUTREACH AND ENGAGEMENT
  • 9. APPROACHES ................................................................................ 27 5.7 READABILITY OF OUTREACH AND ENROLLMENT MATERIALS ............................................................................. 28 6 ENROLLMENT ............................................................................................... ............................................. 29 6.1 ENROLLMENT STRATEGIES .................................................................................... ........... .............................................. 29 6.2 LEVELS OF ENROLLMENT....................................................................... ......................................................................... 29 6.3 ACCOUNT CREATION ............................................................................................... ......................................................... 31 6.4 INFORMATION COLLECTED PRIOR TO INFORMED CONSENT ................................................................................. 31 6.5 INFORMED CONSENT OVERVIEW ............................................................................................... ................................... 31 6.6 ELECTRONIC CONSENT ............................................................................................... ..................................................... 33 6.7 DATA OVERSIGHT AND CHOICE OF LAW ............................................................................................... ...................... 37 6.8 MONITORING ENROLLMENT ............................................................................................... ........................................... 38 7 WHAT IS INVOLVED? PROGRAM PROCEDURES........................................................................
  • 10. ........ 41 7.1 PARTICIPANT-PROVIDED INFORMATION (PPI) ............................................................................................... ........ 42 7.2 USE OF PERSONAL HEALTH TECHNOLOGIES ............................................................................................... .............. 43 7.3 PHYSICAL MEASUREMENTS ............................................................................................... ............................................. 45 7.4 BIOSPECIMEN COLLECTION ............................................................................................... ............................................. 46 7.5 BIOSPECIMEN PROCESSING AND STORAGE ............................................................................................... ................. 48 7.6 ELECTRONIC HEALTH RECORDS (EHRS) ............................................................................................... .................... 51 7.7 DATA LINKAGE ............................................................................................... ................................................................... 51 7.8 EARLY AND LONG-TERM PARTICIPANT INVOLVEMENT ......................................................................................... 53 8 RISKS/BENEFITS ASSESSMENT ............................................................................................... .............. 56 8.1 RISKS ............................................................................................... ..................................................................................... 56 8.2 BENEFITS .......................................................................................... ..... ............................................................................. 58 8.3 RISK/BENEFIT ANALYSIS
  • 11. ............................................................................................... ................................................ 60 9 ISSUES TO CONSIDER ............................................................................................... ................................ 60 9.1 PAYMENT FOR PARTICIPANTS ............................................................................................... ........................................ 60 All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 7 9.2 HANDLING ON-SITE REPORTABLE EVENTS ............................................................................................... ................ 61 9.3 PARTICIPATION OPTIONS: DEACTIVATE AND WITHDRAWAL PROCEDURES ..................................................... 62 9.4 DESTRUCTION OF SPECIMENS........................................................................... ............................................................. 64 10 ACCESS TO INDIVIDUAL-LEVEL INFORMATION FOR PARTICIPANTS ......................................... 65 10.1 PRINCIPLES OF INDIVIDUAL-LEVEL INFORMATION AVAILABILITY ..................................................................... 65 10.2 INDIVIDUAL-LEVEL PROGRAM INFORMATION ............................................................................................... ........... 65
  • 12. 10.3 INFORMATION ACCESS TECHNOLOGIES ............................................................................................... ....................... 67 10.4 INDIVIDUAL-LEVEL INFORMATION ACCESS PROCESSES........................................................................... .............. 68 10.5 PHYSICAL MEASUREMENTS—RETURN OF MEDICALLY ACTIONABLE RESULTS.............................................. 70 10.6 PARTICIPANT-PROVIDED INFORMATION AND EHR ............................................................................................... . 74 10.7 ACCESS TO BIOSPECIMEN-DERIVED INFORMATION (NON-GENETIC) ................................................................ 74 10.8 ACCESS TO GENOMIC RESULTS ............................................................................................... ....................................... 74 11 CREATION OF THE ALL OF US RESEARCH PROGRAM RESOURCE................................................. 75 11.1 THE RAW DATA REPOSITORY ............................................................................................... ........................................ 75 11.2 THE CURATED DATA REPOSITORY ............................................................................................... ................................ 75 11.3 THE PTSC DATA REPOSITORY ............................................................................................... ....................................... 76 12 ACCESS TO THE RESOURCE FOR RESEARCH ...................................................................................... 77 12.1 ALL OF US DATA ACCESS GOVERNANCE ............................................................................................... ....................... 78
  • 13. 12.2 ACCESS AND USE OF DATA ............................................................................................... .............................................. 79 12.3 ACCESS AND USE OF BIOSPECIMENS ............................................................................................... ............................. 82 12.4 CONTACTING PARTICIPANTS ............................................................................................... .......................................... 82 13 CONFIDENTIALITY, PRIVACY, AND SECURITY .................................................................................. 83 13.1 SECURITY POSTURE ............................................................................................... ........................................................... 84 13.2 FISMA AND ITS SIGNIFICANCE TO THE ALL OF US RESEARCH PROGRAM ......................................................... 84 13.1 OVERVIEW OF PRIVACY AND DATA CONFIDENTIALITY PROTECTIONS .............................................................. 87 14 POST-ENROLLMENT ENGAGEMENT STRATEGY ............................................................................... 91 14.1 CONCEPTUAL FRAMEWORK ............................................................................................... ............................................ 92 14.2 APPROACH TO ENGAGEMENT ............................................................................................... ......................................... 93 14.3 RETENTION ............................................................................................... .......................................................................... 95 15 SITE MONITORING, RECORD KEEPING, AND QUALITY ASSURANCE ........................................... 98
  • 14. 15.1 HPO AND DV ENROLLMENT SITE MONITORING ............................................................................................... ...... 98 15.2 TRAINING EXPECTATIONS ........................................................................................... .... ................................................ 99 16 REFERENCES ............................................................................................... ............................................. 101 17 LIST OF TERMS AND ACRONYMS ............................................................................................... ......... 103 18 LIST OF APPENDICES ............................................................................................... .............................. 107 19 PROTOCOL VERSIONS ............................................................................................... ............................. 108 All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 8 Table of Tables TABLE 0–1: PROGRAM UNIT AWARDEES ............................................................................................... ........................................... 4 TABLE 0–2: PROTOCOL SYNOPSIS
  • 15. ............................................................................................... ......................................................... 9 TABLE 4–1: VULNERABLE POPULATIONS EXCLUDED AT LAUNCH................................................................................ ....... 22 TABLE 7–1: ESTIMATED DURATION OF PARTICIPANT JOURNEY .......................................................................................... 41 TABLE 7–2: SURVEY COMPLETION TIMES ...................................................................................... ......... ....................................... 43 TABLE 7–3: QUESTIONS TO PARTICIPANTS PRIOR TO SCHEDULING THE BLOOD SAMPLE COLLECTION ............ 47 TABLE 9–1: PARTICIPATION OPTIONS ............................................................................................... .............................................. 62 TABLE 10–1: MEDICALLY ACTIONABLE FINDINGS AT THE TIME OF BASELINE PHYSICAL MEASUREMENTS .... 70 TABLE 12–1: DATA ACCESS BY TYPE ............................................................................................... ................................................. 81 TABLE 13–1: THREAT ASSESSMENT ............................................................................................... .................................................. 88 Table of Figures FIGURE 0–1: GOVERNANCE STRUCTURE ............................................................................................... ............................................ 2 FIGURE 1–1: PPI DEVELOPMENT PROCEDURE ............................................................................................... .............................. 12
  • 16. FIGURE 3–1: PARTICIPANT INTERACTION FLOW ............................................................................... ................ ......................... 19 FIGURE 6–1: PARTICIPANT JOURNEY ............................................................................................... ................................................ 30 FIGURE 7–1: BIOSPECIMEN FLOWCHART ............................................................................................... ........................................ 49 FIGURE 7–2: DATA WORKFLOW SAMPLE FOR PARTICIPANTS...................................................................... ......................... 54 FIGURE 10–1: ALL OF US RESEARCH PROGRAM INDIVIDUAL-LEVEL INFORMATION: DATA AND RESULTS......... 66 FIGURE 10–2: DATA FLOW FOR PARTICIPANTS AND HPO STAFF ......................................................................................... 68 FIGURE 10–3 EXAMPLE OF PHYSICAL MEASUREMENT CARD—CO-BRANDED ................................................................ 72 FIGURE 10–4 EXAMPLE OF PHYSICAL MEASUREMENT CARD—5 X7 FORMAT ................................................................ 73 FIGURE 11–1: CURATED DATASET ............................................................................................... ..................................................... 77 FIGURE 13–1: ALL OF US RESEARCH PROGRAM CONNECTIONS AND DATA FLOW ........................................................ 84
  • 17. All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 9 Protocol Synopsis Table 0–2: Protocol Synopsis TITLE All of Us Research Program (All of Us) SPONSOR National Institutes of Health (NIH) FUNDING ORGANIZATION National Institutes of Health (NIH) NUMBER OF SITES Multiple sites through selected Health Care Provider organizations (HPOs) and Direct Volunteer (DV) partners, and sites representing core functions, such as the Biobank, Data and Research Center (DRC), Participant Technology Systems Center (PTSC), other technology partners , and Community Partners. RATIONALE Precision medicine is an approach to disease treatment and prevention that seeks to maximize effectiveness by considering individual variability in genes, environment, and lifestyle. Precision medicine
  • 18. seeks to redefine our understanding of disease onset and progression, treatment response, and health outcomes through the more precise measurement of molecular, environmental, physiologic, and behavioral factors that contribute to health and disease. This understanding will lead to more accurate diagnoses, more rational disease prevention strategies, better treatment selection, and the development of novel therapies. By enrolling a diverse group of one million or more participants who provide questionnaire responses—participant-provided information (PPI), electronic health record (EHR) data, biospecimens, physical measurements, and permission for re-contact—for many years, the All of Us Research Program will have the scale and scope to enable research for a wide range of diseases, both common and rare, as well as increasing our understanding of healthy states. STUDY DESIGN At its core, this is a large longitudinal cohort program with repeated engagement of participants to create a research resource that enables a variety of future observational and interventional studies, some of which will require subsequent IRB approvals. PRIMARY OBJECTIVE To build a robust research resource composed of PPI, environmental,
  • 19. physiologic, genetic, and health data plus biospecimens from one million or more research participants reflecting the diversity of the United States. All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 10 This resource will facilitate the exploration of biological, social, and environmental determinants of health and disease. NUMBER OF PARTICIPANTS AND ENROLLMENT MODES One million or more individuals willing and able to answer questionnaires (PPI), provide biospecimens and physical measurements, share their EHR data, and authorize re-contact will be enrolled via two modes, whichever is most convenient for the participant: through HPOs or DV sites, using digital interfaces. We expect that many more than one million individuals may enroll into the cohort and complete some of these components (see Section
  • 20. 4, Selection of Participants). PARTICIPANT SELECTION CRITERIA Inclusion Criteria: • Adults 18 and older with decisional capacity to consent • Currently reside in the United States or a territory of the United States Exclusion Criteria: • Prisoners at the time of enrollment DURATION OF PARTICIPATION AND DURATION OF STUDY Duration of Study: The All of Us Research Program is expected to last at least 10 years, with active enrollment occurring in the first five years. Duration of Participation: Participation is expected to last for the entire duration of the research program, with regular data contribution and follow-up. PRIMARY ENDPOINT Collection and curation of rich
  • 21. participant health and biospecimen data accessible to the research community, to enable a broad spectrum of research studies. SECONDARY ENDPOINTS Build the infrastructure to enroll participants, collect biospecimens, and securely share health-related data for ongoing research. SAFETY EVALUATIONS Safeguards are in place to maintain the privacy of the participants, the confidentiality of the biospecimens, and the security of the data collected through the research program (see Section 13, Confidentiality, Privacy, and Security). All of Us Research Program—Protocol v1.11 pre02 IRB Approval Date 11 1 Background and Scientific Rationale
  • 22. Our current approach to health care is informed by clinical trials that have sample sizes in the thousands, or tens of thousands, meaning that we typically lack the statistical power to make fine- grained predictions about how a given treatment will affect a given individual. As a result, therapies often fail in practice and most interventions fail to integrate with most patients’ own knowledge and lifestyles. Historically, this approach is characterized by a lack of inclusion and diversity in clinical study; that is, the benefits of precise and personalized interventions may not be accruing equitably across society. Precision medicine is an approach to disease prevention, diagnosis, and treatment that seeks to maximize effectiveness by considering individual variability in genes, environment, and lifestyle. Precision medicine seeks to redefine our understanding of disease onset and progression, treatment response, and health outcomes through the combined analysis of biological, environmental, and behavioral factors that contribute to health and disease. This understanding may lead to more rational disease prevention strategies, more accurate diagnoses, better treatment selection, and the development of novel therapies. The promise of precision medicine can only be achieved with input from a broad population that reflects the true diversity and life experiences of those in the United States. By combining health-related information from one million or more diverse participants, the All of Us Research Program will have the right scale and inclusive scope to enable research for a wide
  • 23. range of diseases, both common and rare. A cohort of this size will have the statistical power to detect associations between genetic and environmental exposures and a wide variety of health outcomes. A deliberately inclusive strategy that prioritizes groups historically underrepresented in biomedical research (UBR) should provide enough power for meaningful subgroup analyses and lead to the most precise medicine for these groups. Outcomes of this research could include novel prevention and screening strategies, earlier and more precise diagnoses, new and more rational use of therapies, and improved understanding of why some people remain healthy despite exposures and risk factors for disease. Coincident with advancing the science of medicine is a changing culture of health care practice and biomedical research that engages individuals as active partners. The All of Us Research Program aims to actively engage participants and their advocates in all aspects of the research program, including governance, oversight, design, conduct, dissemination, and evaluation. Participants will not only provide their biological, health, behavioral, and environmental data, they will also be able to access their information, learn about the research being conducted, and be partners in the discovery process. This ongoing partnership between the research program and participants is described in Section 14, …